<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761657</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-SM4592-017</org_study_id>
    <nct_id>NCT00761657</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of FG-4592 in Subjects With Anemia and Chronic Kidney Disease Not Requiring Dialysis</brief_title>
  <official_title>A Randomized, Single-blind, Placebo-controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects With Chronic Kidney Disease Not Requiring Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety, tolerability and
      pharmacodynamic effects of 5 different oral doses of FG-4592 administered two times or three
      times weekly for up to 4 weeks to subjects with Chronic Kidney Disease not requiring
      dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of FG-4592</measure>
    <time_frame>16 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize Trough concentrations of FG-4592</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects of FG-4592 on anemia</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FG-4592 1.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FG-4592 1.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FG-4592 2.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FG-4592 2.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FG-4592 3.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FG-4592 0.7 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>FG-4592 1.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>FG-4592 1.5 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>FG-4592 2.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>FG-4592 2.5 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>FG-4592 3.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days</description>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Placebo Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days</description>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>FG-4592 0.7 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days</description>
    <arm_group_label>G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 75 years of age.

          2. Chronic Kidney Disease stage 3 or 4 with hemoglobin &lt; 11.0 g/dL

          3. Normal iron studies.

          4. Normal folate and vitamin B12 levels.

          5. Liver function tests within normal limits at screening.

          6. Absence of active or chronic rectal bleeding.

          7. Absence of diagnosis of age-related macular degeneration (AMD), diabetic macular edema
             or diabetic proliferative retinopathy that is likely to require treatment during the
             trial.

          8. Female subjects must not be pregnant nor breast-feeding.

          9. Male subjects with partners who can have children must agree to use a medically
             acceptable method of contraception.

        Exclusion Criteria:

          1. Seropositive for HIV.

          2. History of chronic liver disease.

          3. History of polycystic kidney disease (PKD).

          4. Uncontrolled hypertension (diastolic BP &gt;110 mm Hg or systolic BP &gt;170 mm Hg at
             screening).

          5. New York Heart Association Class III or IV congestive heart failure.

          6. Recent myocardial infarction or acute coronary syndrome.

          7. History of myelodysplastic syndrome.

          8. Any history of malignancy or a known genetic predisposition for developing cancer
             (e.g., with diagnostic markers suggesting a genetic predisposition of cancer) except
             for curatively resected basal cell carcinoma of skin, squamous cell carcinoma of skin,
             cervical carcinoma in situ, or resected benign colonic polyps.

          9. Active inflammatory infection or chronic inflammatory disease

         10. Any clinically significant and uncontrolled medical condition considered a high risk
             for participation in an investigational study.

         11. Blood clots within 4 weeks.

         12. History of ongoing hemolysis or diagnosis of hemolytic syndrome.

         13. Known history of bone marrow fibrosis.

         14. History of hemosiderosis or hemochromatosis.

         15. Androgen therapy within 12 weeks.

         16. Red blood cell transfusion within 12 weeks.

         17. Therapy with an erythropoiesis stimulating agent (ESA) such as human recombinant
             erythropoietin within the past 60 days.

         18. Intravenous iron supplementation within the past 60 days.

         19. Currently taking acetaminophen &gt;2.6 g/day.

         20. History of prior organ transplantation.

         21. Alcohol consumption greater than 3 or more drinks per day within the past year.

         22. Use of an investigational medication or participation in an investigational study
             within 4 weeks preceding Day 1.

         23. Positive urine toxicology screen for a substance that has not been prescribed for the
             subject.

        For subjects aged over 75 years but who otherwise meet all other patient selection
        criteria, subjects will be evaluated on a case-by-case basis and can be included in this
        study, per discretion of sponsor's physician representative such as medical monitor or
        clinical leader.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <zip>80002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westminster</city>
        <state>Colorado</state>
        <zip>80031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>CKD</keyword>
  <keyword>Stage 3 or 4 Chronic Kidney Disease</keyword>
  <keyword>Renal</keyword>
  <keyword>Anemia</keyword>
  <keyword>Oral anemia treatment</keyword>
  <keyword>Hemoglobin levels</keyword>
  <keyword>Blood count</keyword>
  <keyword>Erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

